ABSTRACT
INTRODUCTION/AIM: Long-term efficacy and safety of dichlorphenamide (DCP) were characterized in patients with primary periodic paralysis (PPP). METHODS: Patients with PPP in a double-blind, placebo-controlled study were randomly assigned to receive DCP 50 mg twice daily or placebo for 9 weeks, followed by a 52-week open-label DCP treatment phase (DCP/DCP and placebo/DCP populations). Efficacy (attack rate, severity-weighted attack rate) and safety were assessed in patients completing the study (61 weeks). In this post hoc analysis, efficacy and safety data were pooled from hyperkalemic and hypokalemic substudies. RESULTS: Sixty-three adults (age, 19-76 years) completed the double-blind phase; 47 (74.6%) of these patients completed 61 weeks. There were median decreases in weekly attack and severity-weighted attack rates from baseline to week 61 (DCP/DCP [n = 25], -1.00 [P < .0001]; placebo/DCP [n = 20], -0.63 [P = .01] and DCP/DCP, -2.25 [P < .0001]; placebo/DCP, -1.69 [P = .01]). Relatively smaller median decreases in weekly attack and severity-weighted attack rates occurred from weeks 9 to 61 among patients receiving DCP continuously (n = 26; -0.14 [P = .1] and -0.24 [P = .09]) than among those switching from placebo to DCP after 9 weeks (n = 16; -1.04 [P = .049] and -2.72 [P = .08]). Common adverse events (AEs) were paresthesia and cognition-related events, which typically first occurred within 1 month of blinded treatment initiation and in rare cases led to treatment discontinuation. Dose reductions were frequently associated with common AE resolution. DISCUSSION: One-year open-label DCP treatment after a 9-week randomized, controlled study confirmed long-term DCP remains safe and effective for chronic use. Tolerability issues (paresthesia, cognition-related AEs) were manageable in most patients.
Subject(s)
Carbonic Anhydrase Inhibitors/therapeutic use , Dichlorphenamide/therapeutic use , Paralyses, Familial Periodic/drug therapy , Adult , Aged , Carbonic Anhydrase Inhibitors/adverse effects , Dichlorphenamide/adverse effects , Double-Blind Method , Female , Humans , Male , Middle Aged , Treatment Outcome , Young AdultABSTRACT
BACKGROUND: Primary periodic paralyses are rare, hereditary skeletal muscle diseases characterized by episodic muscle weakness. Dichlorphenamide was effective and well tolerated in two studies, including one with adolescents. This analysis describes effects of dichlorphenamide among adolescents and adults. METHODS: Patients with primary periodic paralyses in a double-blind, controlled, crossover study were randomized to dichlorphenamide or placebo for nine weeks, with a nine-week or longer between-treatment washout period. Attack rate and severity-weighted attack rate during the final eight weeks of each treatment phase were calculated for adolescents and adults separately. RESULTS: Seven adolescents (10 to ≤17 years) and 66 adults were enrolled; five of seven adolescents were evaluable for efficacy and six for safety. Dichlorphenamide total daily dosing among adolescents was 50 mg (n = 1) or 100 mg (n = 5), and in adults was 105.7 mg (mean; n = 61). In adolescents, the median decrease from baseline in frequency of weekly attacks was greater with dichlorphenamide (-0.96) than with placebo (-0.57), similar to findings in adults (dichlorphenamide, -0.83; placebo, -0.24). Severity-weighted attack frequency was likewise reduced more with dichlorphenamide than with placebo in adolescents and adults. The most common adverse event with dichlorphenamide in adolescents was skin rash (two of six [33%]). In adults, numbness was the most common adverse event (26 of 54 [48%]); skin rash occurred less frequently (10 of 54 [19%]). CONCLUSIONS: Dichlorphenamide was comparably effective and tolerated among a small number of adolescents as well as adults, although types of adverse events differed between groups.
Subject(s)
Carbonic Anhydrase Inhibitors/therapeutic use , Dichlorphenamide/therapeutic use , Paralyses, Familial Periodic/drug therapy , Adolescent , Adult , Aged , Carbonic Anhydrase Inhibitors/adverse effects , Child , Dichlorphenamide/adverse effects , Double-Blind Method , Humans , Middle Aged , Treatment Outcome , Young AdultABSTRACT
Single-and multiple-dose pharmacokinetics and safety were investigated in this phase 1 study of dichlorphenamide, a carbonic anhydrase inhibitor approved in the United States for treatment of primary periodic paralysis. Dichlorphenamide was administered to 6 cohorts (n = 6 each) of healthy adults. Cohorts A through E received single doses of 25-400 mg followed by 50-800 mg/day in divided doses for 10 total doses. Cohort F (safety analysis only) received up to 28 titrated doses from 100-800 mg/day. Plasma for pharmacokinetics sampling was obtained predose and up to 48 hours postdose. Twenty-five of 36 enrolled subjects completed. Median time to maximum plasma concentration ranged from 1.5-3 hours, and mean half-life from 32-68 hours. Mean area under the concentration-time curve from time 0 to tau (length of the dosing interval estimated using the trapezoidal method) and maximum observed plasma concentration increased dose-proportionally after multiple doses. The incidence and severity of adverse events (AEs) were dose-related, with at least one mild AE reported among 17%, 17%, and 67% of patients in cohorts A, B, and C, respectively; and at least one mild-to-moderate AE among 100% of subjects in cohorts D, E, and F. One serious AE of rash was reported in cohort F. Eleven subjects discontinued; 10 due to AEs at 400 or 800 mg/day (cohorts E and F), including 100% of cohort F. Hypokalemia contributed to 5 of 6 discontinuations in cohort F (all 800 mg/day).
Subject(s)
Carbonic Anhydrase Inhibitors/administration & dosage , Dichlorphenamide/administration & dosage , Adult , Carbonic Anhydrase Inhibitors/adverse effects , Carbonic Anhydrase Inhibitors/blood , Carbonic Anhydrase Inhibitors/pharmacokinetics , Dichlorphenamide/adverse effects , Dichlorphenamide/blood , Dichlorphenamide/pharmacokinetics , Drug Administration Schedule , Female , Healthy Volunteers , Humans , Male , Middle Aged , Single-Blind MethodSubject(s)
Carbonic Anhydrase Inhibitors/administration & dosage , Dichlorphenamide/administration & dosage , Hypokalemic Periodic Paralysis/drug therapy , Paralysis, Hyperkalemic Periodic/drug therapy , Carbonic Anhydrase Inhibitors/adverse effects , Carbonic Anhydrase Inhibitors/economics , Dichlorphenamide/adverse effects , Dichlorphenamide/economics , Drug Administration Schedule , Drug Costs , Drug Interactions , Humans , Hypokalemic Periodic Paralysis/diagnosis , Hypokalemic Periodic Paralysis/physiopathology , Paralysis, Hyperkalemic Periodic/diagnosis , Paralysis, Hyperkalemic Periodic/physiopathology , Treatment OutcomeABSTRACT
An 81-year-old man developed hyperkalaemic and hyperchloraemic metabolic acidosis following treatment with a carbonic anhydrase inhibitor for his glaucoma. He had mild renal failure and selective aldosterone deficiency was confirmed. In this case the treatment did not lead to hypokalaemia because of the limited potassium secretory capacity in the renal tubules from selective aldosterone deficiency; rather, it may have led to hyperkalaemia because metabolic acidosis induced by the carbonic anhydrase inhibitor caused transcellular movement of potassium.
Subject(s)
Dichlorphenamide/adverse effects , Glaucoma/drug therapy , Hyperkalemia/chemically induced , Acidosis/chemically induced , Acute Kidney Injury/complications , Aged , Aged, 80 and over , Aldosterone/deficiency , Humans , MaleABSTRACT
The National Registry of Drug-Induced Ocular Side Effects has received 79 case reports of suspected hematopoietic toxicity caused by carbonic anhydrase inhibitors. Twenty-six of these suspected cases (32%) resulted in death secondary to aplastic anemia, thrombocytopenia, or agranulocytosis. In 54 of these 79, adverse reactions (68%) occurred during the first six months of therapy.
Subject(s)
Agranulocytosis/chemically induced , Anemia, Aplastic/chemically induced , Carbonic Anhydrase Inhibitors/adverse effects , Thrombocytopenia/chemically induced , Acetazolamide/adverse effects , Dichlorphenamide/adverse effects , Glaucoma/drug therapy , Humans , Leukopenia/chemically induced , Methazolamide/adverse effects , Pancytopenia/chemically inducedABSTRACT
Two young patients with unimpaired renal and hepatic function were found to have developed metabolic acidosis after treatment for glaucoma and joint pain with a combination of salicylates and carbonic anhydrase inhibitors in normal doses. Carbonic anhydrase inhibitors appear to interact with salicylates to produce serious metabolic acidosis in patients without the predisposing factors generally considered to constitute risks. It is recommended that treatment combining salicylates and carbonic anhydrase inhibitors is either kept to a minimum or avoided.
Subject(s)
Acidosis/chemically induced , Carbonic Anhydrase Inhibitors/adverse effects , Salicylates/adverse effects , Acetazolamide/adverse effects , Adult , Arthritis/drug therapy , Aspirin/adverse effects , Aspirin/analogs & derivatives , Child , Dichlorphenamide/adverse effects , Drug Interactions , Drug Therapy, Combination , Female , Glaucoma/drug therapy , Humans , MaleABSTRACT
An average daily dose of 33 mg of diclofenamide, a carbonic-anhydrase inhibitor, was added to the anti-epileptic medication already employed in 105 cases of severe epilepsy which had shown insufficient clinical improvement. A favourable action on seizures, often accompanied by an improvement in the EEG tracing, was observed in 83 cases. The effect was of long duration in 47 cases in that it lasted for more than a year. It persisted for one to twelve months in a further 17 cases, while in 19 patients, who had reacted favourably to the treatment, medication had to be suspended because of intolerance.
Subject(s)
Dichlorphenamide/therapeutic use , Epilepsy/drug therapy , Adolescent , Adult , Child , Child, Preschool , Clinical Trials as Topic , Dichlorphenamide/administration & dosage , Dichlorphenamide/adverse effects , Drug Evaluation , Female , Humans , Male , Middle Aged , Recurrence , Time FactorsABSTRACT
SWV mice were totally resistant to the teratogenic and embryolethal actions of acetazolamide. The time of maximal sensitivity to acetazolamide-induced ectrodactyly in the CBA/J strain was the middle of day 10; the dose response at this time was studied. Comparison of the responses of the two strains and reciprocal hybrids indicated that sensitivity is a property of the embryo and is not maternally mediated. SWV mice were also resistant to dichlorphenamide which suggests they may be resistant to many or even all teratogenic carbonic anhydrase inhibitors.